|
Market Closed -
Nasdaq
07:00:00 17/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 157.14 USD | -2.87% |
|
-6.66% | -13.96% |
| 15/10 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 08/10 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 8,231 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | -10.6% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 8,084 | 7,810 | 7,344 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | -10.9% | -3.38% | -5.97% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -54.4x | 38.2x | 14.3x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 127x | 22x | 7.41x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.5x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 8.64x | 5.42x | 3.86x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 8.49x | 5.14x | 3.44x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -58x | 39.9x | 16.7x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -54.4x | 31.9x | 10.5x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -153x | 21.9x | 10.9x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.65% | 4.57% | 9.14% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.888 | 4.109 | 11.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 952.6 | 1,519 | 2,134 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -139.3 | 195.7 | 440.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -148.5 | 245.1 | 702.2 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -152 | 221.7 | 626.7 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -147.6 | -421 | -887 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 157.14 | 157.14 | 157.14 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,381 | - | - |
| Announcement Date | 1/3/22 | 27/2/23 | 20/2/24 | 18/2/25 | 23/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -54.41x | 8.49x | -58.03x | -.--% | 8.23B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 20.71x | 7.10x | 10.75x | 1.94% | 394.91B | |
| Weighted average by Cap. | 34.54x | 8.20x | 19.88x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
